Koyfin Home > Directory > Health Care > Revance Therapeutics > Net Change in Cash

Revance Therapeutics Net Change in Cash Chart (RVNC)

Revance Therapeutics annual/quarterly Net Change in Cash from 2012 to 2020.
  • Revance Therapeutics Net Change in Cash for the quarter ending September 09, 2020 was $-24m a 570.07% decrease of -136m year over year
  • Revance Therapeutics Net Change in Cash for the last 12 months ending September 09, 2020 was $281m a 65.16% increase of 183m year over year
  • Revance Therapeutics Annual Net Change in Cash for 2019 was $98m a 313.97% increase of 307m from 2018
  • Revance Therapeutics Annual Net Change in Cash for 2018 was $-209m a 204.73% decrease of -429m from 2017
  • Revance Therapeutics Annual Net Change in Cash for 2017 was $219m a 162.89% increase of 357m from 2016
Other Cash Flow Metrics:
  • Revance Therapeutics Cash Flow from Operations for the quarter ending September 09, 2018 was $-25m a -11.78% increase of 3m year over year
  • Revance Therapeutics Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-14m a -14.44% increase of 2m year over year
  • Revance Therapeutics Total Revenue for the quarter ending September 09, 2018 was $2m a 98.43% increase of 2m year over year
View Chart On Koyfin

Quarterly RVNC Net Change in Cash Data

09/2020$-24m
06/2020$77m
03/2020$115m
12/2019$112m
09/2019$-31m
06/2019$25m
03/2019$-8m
12/2018$28m
09/2018$6m
06/2018$-30m

Annual RVNC Net Change in Cash Data

2019$98m
2018$-209m
2017$219m
2016$-138m
2015$31m
2014$167m
2013$0m
2012$-26m
2011$26m